Onco-Innovations' Inka Health Publishes Framework on Transportability of Real-World Evidence and Use in Health Technology Assessment
Onco-Innovations (OTCQB:ONNVF) announced that subsidiary Inka Health published a technical primer titled Transportability of Non-Local Real-World Evidence in the Journal of Clinical Evaluative Research on November 7, 2025. The primer outlines three foundational principles — consistency, positivity, conditional exchangeability — and describes statistical techniques (matching, weighting, standardization, bias analysis) to adapt non-local RWE for Health Technology Assessment.
Inka Health plans to integrate these methods into its SynoGraph platform to support cross-border oncology evidence use, especially for rare diseases with limited local data.
Onco-Innovations (OTCQB:ONNVF) ha annunciato che la controllata Inka Health ha pubblicato un primer tecnico intitolato Trasportabilità delle Evidenze del Mondo Reale non Locali nel Journal of Clinical Evaluative Research il 7 novembre 2025. Il primer descrive tre principi fondamentali — coerenza, positività, scambiabilità condizionale — e descrive tecniche statistiche (abbinamento, ponderazione, standardizzazione, analisi di bias) per adattare le RWE non locali per l'Health Technology Assessment.
Inka Health intende integrare questi metodi nella sua piattaforma SynoGraph per supportare l'uso di evidenze oncologiche transborderistiche, soprattutto per malattie rare con dati locali limitati.
Onco-Innovations (OTCQB:ONNVF) anunció que la subsidiaria Inka Health publicó un primer técnico titulado Transportabilidad de la Evidencia del Mundo Real No Local en el Journal of Clinical Evaluative Research el 7 de noviembre de 2025. El primer describe tres principios fundamentales — consistencia, positividad, intercambiabilidad condicional — y describe técnicas estadísticas (emparejamiento, ponderación, estandarización, análisis de sesgos) para adaptar la RWE no local para la Evaluación de Tecnologías de la Salud.
Inka Health planea incorporar estos métodos en su plataforma SynoGraph para apoyar el uso de evidencias oncológicas transfronterizas, especialmente para enfermedades raras con datos locales limitados.
Onco-Innovations (OTCQB:ONNVF)은 자회사 Inka Health가 2025년 11월 7일 Journal of Clinical Evaluative Research에 실린 기술 프라이머 비지역 현실세계 증거의 운송성를 발표했다고 발표했다. 프라이머는 세 가지 기본 원칙 — 일관성, 양성, 조건부 교환가능성 — 을 개요하고, 로컬이 아닌 RWE를 건강기술평가에 맞게 조정하기 위한 방법으로 매칭, 가중, 표준화, 편향 분석 등의 통계 기법을 설명한다.
Inka Health는 이 방법들을 자사의 SynoGraph 플랫폼에 통합하여 국경 간 암 증거 사용을 지원하고, 특히 로컬 데이터가 제한된 희귀 질환에 초점을 맞출 계획이다.
Onco-Innovations (OTCQB:ONNVF) a annoncé que sa filiale Inka Health a publié un primer technique intitulé Transportabilité des preuves du monde réel non localisées dans le Journal of Clinical Evaluative Research le 7 novembre 2025. Le primer décrit trois principes fondamentaux — la cohérence, la positivité, l’échangeabilité conditionnelle — et décrit des techniques statistiques (appariement, pondération, standardisation, analyse des biais) pour adapter les ECR non locaux à l’évaluation des technologies de santé.
Inka Health prévoit d’intégrer ces méthodes dans sa plateforme SynoGraph afin de soutenir l’utilisation transfrontalière des évidences en oncologie, en particulier pour les maladies rares avec des données locales limitées.
Onco-Innovations (OTCQB:ONNVF) gab bekannt, dass die Tochtergesellschaft Inka Health einen technischen Primer mit dem Titel Transportierbarkeit von nicht lokalen Real-World-Evidences in der Journal of Clinical Evaluative Research am 7. November 2025 veröffentlicht hat. Der Primer skizziert drei grundlegende Prinzipien — Konsistenz, Positivität, bedingte Austauschbarkeit — und beschreibt statistische Techniken (Matching, Gewichtung, Standardisierung, Bias-Analyse), um nicht lokale RWE für die Gesundheits-Technologie Bewertung anzupassen.
Inka Health plant, diese Methoden in seine Plattform SynoGraph zu integrieren, um die grenzüberschreitende Nutzung von onkologischen Evidenzen zu unterstützen, insbesondere für seltene Krankheiten mit begrenzten lokalen Daten.
Onco-Innovations (OTCQB:ONNVF) أعلنت أن الشركة التابعة Inka Health نشرت مقدمة تقنية بعنوان قابلية نقل أدلة الواقع الحقيقي غير المحلية في مجلة Journal of Clinical Evaluative Research في 7 نوفمبر 2025. وتوضح المقدمة ثلاث مبادئ أساسية — الاتساق، الإيجابية، قابلية التبادل الشرطي — وتصف تقنيات إحصائية (المطابقة، التحجيم، التوحيد القياسي، تحليل التحيز) لتكييف RWE غير المحلي لتقييم تكنولوجيا الصحة.
تخطط Inka Health لدمج هذه الأساليب في منصتها SynoGraph لدعم الاستخدام عبر الحدود للأدلة في مجال الأورام، خاصة للأمراض النادرة ذات البيانات المحلية المحدودة.
- None.
- None.
VANCOUVER, BC / ACCESS Newswire / November 7, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") is pleased to announce that its subsidiary, Inka Health Corp. ("InkaHealth"), has published a technical primer[1] on the transportability of real-world evidence (RWE) titled Transportability of Non-Local Real-World Evidence and Its Relevance to Health Technology Assessment in the Journal of Clinical Evaluative Research (JCER). This primer, co-authored with experts at AstraZeneca Canada, addresses a critical challenge in global healthcare decision-making by demonstrating how advanced statistical transportability methods can adapt medical evidence from one country for use in another. These methods have the potential to accelerate regulatory approvals and improve patient access to innovative therapies, particularly in rare diseases where local data are often limited.
The primer outlines the three foundational principles required for reliable cross-border evidence sharing, which are consistency, positivity, and conditional exchangeability. By applying these golden rules, global regulators, health technology assessment bodies, and industry stakeholders gain a practical framework to evaluate the relevance of non-local RWE. The article also details proven statistical techniques including matching, weighting, standardization, and bias analysis that will be integrated into Inka Health's SynoGraph platform to address differences in patient populations. This ensures that real-world oncology data from various regions can be more confidently used to inform healthcare decisions worldwide.
These approaches are especially important for rare disease drug approvals where patient populations are small and local evidence is often lacking. By enabling non-local data to be used effectively, the primer offers a potential solution to this bottleneck, ultimately helping to speed up approval of access to life-saving treatments.By incorporating these transportability methods into SynoGraph, Inka Health is advancing the use of artificial intelligence to overcome global data challenges in oncology, supporting more precise, timely, and evidence-based treatment decisions worldwide.
"This primer marks a pivotal step toward making global health data more accessible and actionable. By harnessing advanced statistical methods alongside AI-powered tools like SynoGraph, we can break down geographic barriers in oncology research. This publication is instrumental in exploring applications for transportability in real-world oncology settings and finding ways to help accelerate the delivery of innovative treatments to patients who need them most, particularly in rare disease communities where data scarcity has long been a challenge," stated Paul Arora, Co-Founder of Inka Health.
AstraZeneca Canada became a client of Inka Health on September 23, 2024, prior to Inka Health becoming part of Onco-Innovations on February 3, 2025. AstraZeneca is not an investor in Onco-Innovations. Any references to AstraZeneca Canada are only to the real-world evidence and analytic methods publications being developed under the services agreement with Inka Health.
About Inka Health
Inka Health is an AI-driven analytics company revolutionizing oncology research and drug development through advanced causal AI. Its proprietary platform, SynoGraph, leverages AI-powered causal inference to identify which cancer patients are most likely to respond to specific treatments, advancing precision medicine. By integrating diverse multimodal medical data, including genomics, transcriptomics, and proteomics, SynoGraph uncovers hidden insights that can optimize treatment decisions and clinical trial design. With this cutting-edge technology, Inka Health aims to help pharmaceutical companies accelerate drug development, reduce trial failures, and bring life-saving therapies to market faster.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the Company's business and plans, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to receive regulatory approval in respect of the Private Placement, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward- looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
[1] A primer is an introductory text that provides a basic explanation of a subject, designed to help readers gain a foundational understanding.
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
FAQ
What did Inka Health publish about RWE transportability on November 7, 2025 for ONNVF?
How will Inka Health's SynoGraph platform use the transportability methods for ONNVF?
What are the three foundational principles for RWE transportability mentioned by ONNVF?
How could Inka Health's methods affect rare disease approvals referenced by ONNVF?
When did AstraZeneca Canada become a client of Inka Health mentioned in the ONNVF release?
Is AstraZeneca an investor in Onco-Innovations according to the ONNVF announcement?
